Health - Thursday, April 16, 2026

Dr. Erica Schwartz is seen as a highly qualified traditional choice and tapping her is the strongest signal yet that the administration is veering away from vaccine skepticism this election year.

The ruling delivers clarity on the path forward for addressing problems with the No Surprises Act.

Schwartz's background as a physician with plenty of government service experience will likely be popular among lawmakers.

This week on "The Readout LOUD," a pancreatic cancer breakthrough and new hope for an off-the-shelf CAR-T treatment in lymphoma.

RFK Jr. focused on President Trump's health care agenda and largely avoided vaccines.

A rogue set of “zombie” immune cells may be driving aging and fatty liver disease by flooding tissues with inflammation. Researchers found these cells accumulate with age and high cholesterol—and can make up most of the liver’s immune cells in older mice. When scientists removed them, liver damage was dramatically reversed, even without diet changes.

Scientists are raising a provocative hypothesis about GLP-1 drugs for obesity: Perhaps targeting the GLP-1 hormone isn't actually necessary to achieve effective weight loss.

A massive, nearly 20-year study tracking over 650,000 Americans with irritable bowel syndrome is raising new questions about the long-term safety of common treatments. Researchers found that some widely used medications—including antidepressants and certain antidiarrheal drugs—were linked to a small but noticeable increase in the risk of death over time.

New research suggests that aiming for a lower blood pressure target may deliver bigger heart health benefits than previously thought. Using large datasets and simulation models, scientists found that keeping systolic blood pressure below 120 mm Hg could reduce the risk of heart attack, stroke, and heart failure more than higher targets.

The review said a certain class of drugs had little clinical benefit, but many Alzheimer’s experts criticized the analysis, saying it unfairly lumped failed drugs with two recently approved treatments.